ArticleMolecular neurobiology2025
Contrasting Effects of Clozapine and Risperidone on Cholesterol Metabolism, Synaptic Proteins, and Transcriptional Regulation in Human LUHMES Neurons.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Antipsychotic drugs elicit complex cellular responses in neurons, yet the molecular mechanisms underlying their actions remain incompletely understood. Here, we employed deep proteomic profiling (DDA/DIA-MS) in LUHMES-derived dopaminergic neurons to explore the distinct proteomic profile induced by clozapine and risperidone. Pathway analysis revealed that clozapine robustly upregulated lipid metabolic pathways, particularly those involved in cholesterol and fatty acid biosynthesis. Conversely, risperidone primarily enhanced oxidative phosphorylation and modulated synaptic architecture and protein metabolic-pathways. Functional enrichment further indicated that clozapine promotes sterol metabolism, neuronal viability, and neurite outgrowth-hallmarks of neurotrophic activity - while simultaneously suppressing neurotransmission. Importantly, quantitative analysis of the nuclear subproteome enabled us to map these opposing regulatory hubs with high precision. Mechanistically, clozapine induced a transcriptionally repressive state, marked by downregulation of chromatin-opening factors CHD5 and DPF3 (BAF complex components) and HMGN1. In parallel, upregulation of the transcriptional repressor CIC reinforced this repressive signature, suggesting diminished chromatin accessibility. Furthermore, downregulation of activity-dependent regulators CRTC3 and JUNB pointed to an attenuation of excitability-driven gene expression. In contrast, risperidone upregulated TCF4, TCF7L1, FOS, HMGN1, and coactivators RREB1 and NCOA3, promoting Wnt signaling, chromatin accessibility and synaptic plasticity. Taken together, our data unveil distinct proteomic, transcriptional and epigenetic programs orchestrated by clozapine and risperidone, providing novel molecular insights into their divergent clinical actions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.